_-81-189.jpg "Химиотерапия при раке без побочных эффектов. Пациенту 81 год. Химия плюс Синтезит. Отзыв №189 from folfiri Video Screenshot Preview")
GalleryPlay Video:
(Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
⏲ Duration: 7 min 95 sec
✓ Published: 24-Mar-2022
✓ Published: 24-Mar-2022
Description:
В данном видео Виктория Георгиевна 1940 года рождения рассказывает о результатах лечения рака поджелудочной железы. с апреля по август она прошла 2 курса химиотерапии Folfiri, параллельно употребляя Синтезит. В результате лечения опухоль сократилась на 52 % в сравнении с baseline. В
В данном видео Виктория Георгиевна 1940 года рождения рассказывает о результатах лечения рака поджелудочной железы. с апреля по август она прошла 2 курса химиотерапии Folfiri, параллельно употребляя Синтезит. В результате лечения опухоль сократилась на 52 % в сравнении с baseline. В
Share with your friends:
Whatsapp | Viber | Telegram | Line | SMS
Email | Twitter | Reddit | Tumblr | Pinterest
Related Videos
_tribe-2-folfox-or-folfiri-with-bevacizumab-in-mcrc.webp "OncLiveTV")
_aflibercept-plus-folfiri-in-polish-patients-with-metastatic-colorectal-cancer.webp "VJOncology")
⏲ 2 minutes 29 seconds 👁 72
_colorectal-cancer-understanding-the-impact-of-results-from-calgb-swog-80405-plenary-folfiri-or-mfolfox6-with-beva.webp "The ASCO Post is pleased to present this special video series of interviews by and with leaders in oncology as recorded live at ASCO's 50th Annual Meeting in Chicago. Click on the thumbnail to view the entire interview.nnAlok A. Khorana, MD, Director, GI Malignancies Program, Vice Chair for Clinical Sciences, Taussig Cancer Center, Cleveland Clinic, discusses the CALGB/SWOG 80405 study presented during the plenary session at this year's ASCO Annual Meeting.")
⏲ 3 min 89 sec ✓ 20-Jun-2014
_colorectal-cancer-folfox-versus-folfiri-in-the-mavericc-trial.webp "OncLiveTV")
_esmo-2022-highlights-commentary-and-analysis.webp "Dr Bishal casts his ascerbic eye over the key studies from ESMO 2022.nnStarting with a commentary on the difficulties of oncologists from LMICs attending such meetings, he goes on to cover both the early cancer setting and de-escalation of treatmentnnHe covers the following studies:nn- CANOPY-A: Phase III study of canakinumab as adjuvant therapy in patients with completely resected non-small cell lung cancernn- Charles Swanton / air pollutionnn- IMmotion010: Efficacy and safety from the phase II")
_understanding-your-treatment-folfiri-avastin-therapy.webp "charlottecancer")
_folfiri-side-effects.webp "Shannon Warr")
_heinz-josef-lenz-md-on-metastatic-colorectal-cancer-results-of-the-mavericc-study.webp "Heinz-Josef Lenz, MD, of the USC Norris Comprehensive Cancer Center, discusses the findings of this phase II study of mFOLFOX6-bevacizumab vs FOLFIRI-bevacizumab with biomarker stratification in patients with mCRC. (Abstract 493)")
⏲ 2 min 14 sec ✓ 24-Jan-2016
_tribe-2-folfox-or-folfiri-with-bevacizumab-in-mcrc.jpg)
_aflibercept-plus-folfiri-in-polish-patients-with-metastatic-colorectal-cancer.jpg)
_colorectal-cancer-understanding-the-impact-of-results-from-calgb-swog-80405-plenary-folfiri-or-mfolfox6-with-beva.jpg)
_colorectal-cancer-folfox-versus-folfiri-in-the-mavericc-trial.jpg)
_esmo-2022-highlights-commentary-and-analysis.jpg)
_understanding-your-treatment-folfiri-avastin-therapy.jpg)
_folfiri-side-effects.jpg)
_heinz-josef-lenz-md-on-metastatic-colorectal-cancer-results-of-the-mavericc-study.jpg)
![[+]](/images/menu.gif){kind=small}